Skip to content

Peter Heerma, EVP, Chief Commercial Officer at Travere Therapeutics, sold TVTX on Sep 16, 2026

Data as of Oct 16

▼ SELL$5M79,113 shares at $63.65Peter Heerma EVP, Chief Commercial OfficerTVTX Travere Therapeutics, Inc.
Watch TVTX
Traded
Sep 16, 2026
Disclosed
Sep 17, 2026
Filed
1 day after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Peter Heerma, EVP, Chief Commercial Officer at Travere Therapeutics, sold TVTX on Sep 16, 2026TRADEDDISCLOSED
TVTXSimilar stocks (XLV — its sector index fund), rebased to TVTX's price on the disclosure day
TVTX since disclosure
−23.4%
after the sale
Similar stocks (XLV) since disclosure
+4.7%
XLV — its sector index fund

Change in closing price from Sep 17, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLPeter Heerma EVP, Chief Commercial OfficerTVTX Travere Therapeutics, Inc.$539Kdisclosed Sep 17 · filed the same day
  2. ▼ SELLPeter Heerma EVP, Chief Commercial OfficerTVTX Travere Therapeutics, Inc.$5.9Mdisclosed Sep 17 · filed 1 day after the trade
  3. ▼ SELLPeter Heerma EVP, Chief Commercial OfficerTVTX Travere Therapeutics, Inc.$93.5Kdisclosed Sep 17 · filed 2 days after the trade
  4. ▼ SELLPeter Heerma EVP, Chief Commercial OfficerTVTX Travere Therapeutics, Inc.$1.7Mdisclosed Sep 17 · filed 2 days after the trade
  5. ▼ SELLPeter Heerma EVP, Chief Commercial OfficerTVTX Travere Therapeutics, Inc.$4.5Mdisclosed Sep 17 · filed 2 days after the trade
  6. ▼ SELLPeter Heerma EVP, Chief Commercial OfficerTVTX Travere Therapeutics, Inc.$89.1Kdisclosed Sep 17 · filed 2 days after the trade

See every trade on TVTX →